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ABSTRACT 
Objective. To assess the occurrence and extent of interstitial lung disease (ILD) in patients with 
juvenile mixed connective tissue disease (JMCTD), compare pulmonary function in patients and 
matched controls, explore associations between ILD and disease-related variables, and examine 
progression of pulmonary manifestations over time.  
Methods. A cohort of 52 JMCTD patients were examined in a cross-sectional study after mean 16.2 
(SD 10.3) years disease duration with high-resolution computed tomography (HRCT) and pulmonary 
function tests (PFTs) comprising spirometry, diffusion capacity of carbon monoxide (DLCO) and total 
lung capacity (TLC). Matched controls were examined with PFTs. Previous HRCT and PFTs were 
available in 37 and 38 patients, respectively; mean 8.8 and 10.3 years before study inclusion.  
Results. Compared to controls, JMCTD patients had lower forced vital capacity (FVC), DLCO, and TLC 
(p<0.01). The most frequent abnormal PFT was DLCO in 67% of patients vs. 17% of controls (p<0.01). 
Fourteen patients (27%) had ILD on HRCT. Most had ILD in <10% of their lungs. ILD was associated 
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with low values for FVC and TLC, but not with DLCO. HRCT findings did not progress significantly over 
time, but FVC declined (p<0.01).  
Conclusions. Compared to controls, JMCTD patients had impaired pulmonary function. ILD was 
present in 27% of patients after mean 16 years of disease duration, mostly as mild disease, and did 
not progress. ILD seems to be less common in juvenile than in adult-onset MCTD, and ILD in JMCTD 
seems mostly mild and stable over time.  
Key index terms: mixed connective tissue disease, interstitial lung disease, pulmonary fibrosis, 
paediatric rheumatology, autoantibodies, outcome research 
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Mixed connective tissue disease (MCTD) is a rare autoimmune disease characterised by 
serum autoantibodies directed against ribonucleoprotein (anti-RNP), and with clinical 
findings that include Raynaud phenomenon, puffy hands, as well as features of systemic 
sclerosis (SSc), systemic lupus erythematosus (SLE) and/or polymyositis.  
According to the diagnostic criteria for MCTD described by Kasukawa and colleagues, 
pulmonary manifestations comprise pulmonary fibrosis, restrictive lunge disease (vital 
capacity (VC) <80% of predicted) and/or reduced diffusion capacity of carbon monoxide 
(DLCO) <70% of predicted (1). In adult MCTD, the prevalence of pulmonary manifestations, 
particularly interstitial lung disease (ILD), has been found to range from 35% to 78%, and to 
represent a major cause of morbidity and mortality (2-7). The prognosis in MCTD seems to 
vary from mild disease, as initially described by Sharp et al. (8), to a disease with severe 
complications, such as pulmonary fibrosis and pulmonary arterial hypertension (4, 9).  
Disease onset during childhood or adolescence (before 18 years of age) has been reported to 
occur in 7−23% of all MCTD cases (10, 11). Data on lung involvement in juvenile MCTD are 
scarce. Aaløkken et al. (12) found evidence of ILD in 25% of 24 patients with juvenile MCTD, 
mostly as very mild disease. Further, Mier et al. (13) described ILD in three of ten patients in 
a subpopulation believed to be at risk. The prevalence and extent of ILD observed in juvenile 
MCTD was lower than that reported in most studies on adult MCTD (2-7). Progression of 
lung disease in adult onset MCTD has been shown to be modest (3, 6). Nevertheless, studies 
focusing on the long-term outcome of pulmonary manifestations in patients with juvenile 
MCTD are lacking. 
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Retrospective, small studies on juvenile MCTD have described reduced DLCO in 15−42%, and 
restrictive lung disease in 24−64% of patients (13-15). However, no research team has 
compared pulmonary function with controls from a general population. Whether there is a 
relationship between pulmonary function, ILD and other disease-related variables in juvenile 
MCTD is not known. 
Herein, we aimed to: (i) examine and assess the occurrence and extent of ILD in juvenile 
MCTD in a representative nationwide cohort; (ii) compare pulmonary function in patients 
with juvenile MCTD with age- and sex-matched controls from a general population; (iii) 
examine ILD progression and changes in pulmonary function over time; (iv) evaluate possible 
associations between pulmonary findings and disease-related variables.   
 
METHODS  
Patients and controls 
The current cross-sectional study was performed at Oslo University Hospital (OUH) from 
March 2013 to June 2015.  
Inclusion criteria were: fulfilment of the criteria for the diagnosis of MCTD set by Kasukawa 
and colleagues (1) or Alarcón-Segovia and Villareal; (16) symptom onset before the age of 18 
years; and a clinical diagnosis of MCTD confirmed by a rheumatologist or paediatrician. 
Patients were identified through multiple acquisition routes and a nationwide approach, 
identification and inclusion have been described in detail previously (17).  Sixty two patients 
were initially identified, of these patients three were deceased, three did not wish to 
participate, one did not respond to our enquiries, and three had developed clinical SLE and 
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were excluded. Thus, 52 patients with juvenile MCTD comprised our study population. 
Controls matched for age and sex were selected randomly from the Norwegian population 
register. Controls with a history of autoimmune disease necessitating immunosuppressive 
medication, heart disease and/or lung disease (other than mild asthma) were excluded. 
Informed consent was obtained from all participants and the parents of patients and 
controls <16 years old, according to the Declaration of Helsinki. The study protocol was 
approved by the Regional Ethics Committee for Medical Research (2012/1721). 
 
Clinical data 
Patients and controls underwent a thorough clinical examination undertaken by the main 
investigators (SOH or VL). Clinical parameters during the entire disease course and upon 
examination were obtained from medical records and patient interviews. Through 
examination of medical records and available data from a former study done by our research 
team (12), previous HRCT images (Time 1) were available in 37 patients from at least 2 years 
before the cross sectional examination (Time 2), and previous PFTs were available in 38 
patients. The mean time-span between the first HRCT and the second HRCT was 8.3 years 
(SD 2.7), and for the PFTs it was 10.3 years (SD 1.0). Smoking habits and level of physical 
activity were obtained from questionnaires.  
 
Acquisition and analyses of CT images 
HRCT was undertaken in patients only, and obtained in the supine position, during deep 
inspiration and breath-hold. Images were reconstructed in sections of thickness measuring 
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1–1.25 mm with 10-mm intervals and at sections of thickness measuring 2.5 mm 
reformatted in the axial, coronal, and sagittal planes. The images were reviewed by two 
experienced chest radiologists blinded to clinical information on a Picture Archiving and 
Communication System (PACS). The presence, extent and distribution of ILD was evaluated 
according to the CT criteria of ILD recommended by The Nomenclature Committee of the 
Fleischner Society (18). These criteria comprised reticular pattern (i.e., the coarseness of 
fibrosis), ground-glass opacities, traction bronchiectasis, interlobular septal thickening, and 
airspace consolidations. The reticular pattern was classified into three grades: 1 (fine 
intralobular fibrosis without evident cysts); 2 (mostly microcystic reticular pattern involving 
air spaces ≤4 mm in diameter); 3 (a predominantly macrocystic reticular pattern with air 
spaces >4 mm in diameter). HRCT findings were reviewed in four zones divided in a 
craniocaudal manner by the aortic arch, carina, and inferior pulmonary veins. The extent of 
fibrosis was expressed as a percentage of the TLV. Area measurements were done precisely 
by drawing a freehand region of interest on the PACS screen.  
Pulmonary function tests 
All patients and controls performed PFTs according to a standardized protocol and guidelines 
set by the American Thoracic Society/European Respiratory Society (ATS/ERS) (19, 20) and 
included spirometry, determination of static lung volumes and gas diffusing capacity. All 
measurements were made using an automated Vmax V6200 system (VIASYS Respiratory Care, 
Yorba Linda, CA, USA). Recorded variables were forced vital capacity (FVC), forced expiratory 
volume in 1 s (FEV1), total lung capacity (TLC), DLCO, and DLCO divided by alveolar volume 
(VA). The values were recorded in absolute terms and as the percentage of the predicted 
value. Predicted values were derived from reference equations for each sex, with age and 
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height as predictor variables. Low values for FVC, FEV1, DLCO and TLC were defined as <80% 
of predicted; a low value for FEV1/FVC was defined as <0.70. These cut-off points correspond 
to the lower 5th percentiles in reference material, and are in accordance with ERS 
recommendations (21).  
 
Six-minute walk test (6MWT) 
The 6MWT was carried out on a straight indoor line measuring 35 m according to ATS 
guidelines (22) All participants scored their level of exhaustion on a modified Borg scale (23) 
using values from 0 (no dyspnoea) to 10 (maximal exhaustion).  
 
Statistical analyses 
Differences between patients and controls, and between patients at Time 1 and Time 2, 
were tested with the paired-samples t-test for continuous, normally distributed variables, 
Wilcoxon’s rank sum test for non-normally distributed variables, and McNemar’s test for 
categorical variables. To test differences between patients with and without ILD, we used 
the independent samples t-test for continuous normally distributed variables, Mann–
Whitney U-test for non-normally distributed variables, and the χ2 test or Fisher’s exact test 
was used to test differences in categorical variables. Correlations between extent of ILD, 
DLCO and FVC were determined by the Spearman correlation coefficient. To identify factors 
associated with ILD, we undertook univariable logistic regression analyses on disease-related 
variables from the time of diagnosis. Statistical analyses were undertaken with SPSS v22.0 




The patients were mean 28.0 (SD 10.3) years upon examination (median 27.4; range 11.8–
53.8 years) and had a median duration of disease of 15.7 (range 0.6–41.2) years from 
symptom onset (Table 1). The controls were mean 29.0 (SD 10.2) years. 
Compared with controls, patients were shorter (166.0 vs. 170.1 cm, p =0.016), and had a 
lower body weight (63.0 vs. 68.1 kg, p =0.033). Patients and controls reported a similar 
amount of physical activity and smoking habits. Two patients reported dyspnoea upon 
exertion, one of whom had coronary artery disease. None of the controls reported 
pulmonary symptoms. 
Pulmonary function in patients and controls 
PFT values were impaired in 69% of the juvenile MCTD patients and 25% of controls 
(p<0.001) (Table 2). The most commonly impaired PFT was DLCO (low in 67% of patients and 
17% of controls, p<0.001). FVC was impaired in 21% of patients and zero controls (p < 0.001). 
TLC was impaired in 12% of patients and zero controls (p =0.009). Patients walked a mean 65 
meters shorter on 6MWT than controls (p =0.002). PFTs and the 6MWT remained 
significantly lower in patients than in their matched controls even after excluding patients 
with ILD on HRCT (data not shown).  
HRCT findings in patients 
Fourteen patients (27%) had ILD on HRCT (reticular pattern, ground-glass attenuation, 
interlobular septal thickening, airspace consolidations and/or traction bronchiectasis) (Table 




The extent of ILD was a median of 4% (range 1–75%) of the lung volume. Most (11/14) cases 
showed involvement of ≤10% of TLV (Figure 1). The remaining three patients had 12%, 18% 
and 75% of the lung parenchyma affected, respectively. Of the 14 patients with ILD, only the 
patient with 75% involvement of the lung reported pulmonary symptoms (dyspnoea upon 
exertion).  
A reticular pattern was most often found in the basal lung zone (11/14 patients, 79%). Seven 
of 14 (47%) cases had findings between the inferior pulmonary veins and the level of the 
carina, 6/14 (40%) between the level of the carina and aortic arch, and 3/14 (20%) above the 
aortic arch.  
Associations between ILD and patient characteristics, disease variables and PFTs  
A higher proportion of patients with ILD had low FVC (43% vs. 14%, p =0.023) and low TLC 
(36% vs. 3%, p =0.002) compared with those without ILD (Table 4). Patients without ILD had 
more often been treated with corticosteroids (90% vs. 64%, p = 0.033) and anti-malarial 
agents (92% vs. 57%, p = 0.003) than those with ILD. The use of corticosteroids (but not anti-
malarial agents) correlated with SLE-like disease at the time of examination (r = 0.41, p 
=0.003). The extent of ILD correlated negatively with FVC%-predicted (ρ = −0.64, p =0.01) 
and DLCO%-predicted (ρ = −0.81, p <0.01) at Time 2, but not with other disease-related 
variables at the diagnosis or after a mean of 16 years (data not shown).  
 
Progression of HRCT findings and changes in PFT values  
Changes on HRCT and in PFT values in 37 and 38 patients, respectively, over a median of 8.3 
and 10.3 years are shown in Table 5. Values of FVC and FEV1 declined significantly, but the 
DLCO was stable from Time 1 to Time 2. There was no significant increase in ILD findings 
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with regard to the extent, presence or grade of the reticular pattern between Time 1 and 
Time 2.  
DISCUSSION  
In this long-term outcome study of 52 juvenile MCTD patients, we found ILD in 27% after 
mean disease duration of 16.2 years. Most cases had <10% of lung parenchyma involved. 
Compared with controls, patients had lower values for FVC, DLCO and TLC. ILD was 
associated with low values for FVC and TLC. No significant progression in ILD was observed 
over time. This is the first systematic case-control study on pulmonary manifestations, and 
the first to assess the presence and progression of ILD in an unselected cohort of juvenile 
MCTD patients. 
The prevalence of ILD in adult MCTD has been reported to be 35–78% (2-7). Recently, 
Reiseter et al. observed ILD in 41% of 119 patients after a mean duration of disease of 16.5 
years (3). In our cohort of juvenile MCTD cases, a lower prevalence of 27% of cases with ILD 
was noted even though our patients had a comparable long duration of disease. Two studies 
on juvenile MCTD have also reported the ILD prevalence to be in the lower range. Mier et al. 
(13) found pulmonary fibrosis on CT in 30% of 10 patients believed to be at risk of ILD. 
Aaløkken and colleagues reported a prevalence of ILD of 25% in 24 juvenile MCTD patients 
after a median duration of disease of 10.5 years (12). In juvenile SSc and dermatomyositis, 
the prevalence of ILD has been reported to be 21% and 14%, whereas in juvenile SLE, ILD 
rarely occurs(24-26). Thus, a prevalence of ILD of 27% in our study is in accordance with that 
reported in juvenile MCTD, but lower than that reported in most studies of adult MCTD 
patients. However, compared to other paediatric connective tissue diseases, ILD is a 
frequent finding in juvenile MCTD. 
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Most of our patients had mild fibrosis, and only 6% had lung involvement of >10%. These 
findings are in accordance with those reported by Aaløkken and colleagues in juvenile MCTD 
patients(12). With respect to adult MCTD, however, Reiseter et al. found a much higher 
proportion (17%) of cases with involvement of >10% of TLV(3). Furthermore, in a large cross-
sectional study with 126 adult patients, Gunnarsson et al. reported that 19% of cases had 
severe fibrosis(2). According to our results, not only the prevalence, but also the severity of 
ILD in juvenile MCTD seems to be lower than that in adult MCTD.  
Impaired lung function was found in 69% of our patients, and values of FVC, FEV1, DLCO and 
TLC were reduced significantly compared with those in controls. The most commonly 
impaired PFT was DLCO, which was noted in 65% of cases. However, on a group level, the 
reduction was only moderate. Patients with ILD and impaired PFTs were mainly 
asymptomatic; only one patient reported symptoms of ILD. The 6MWT was clearly reduced 
compared with that of controls, but within the expected normal range(27), which supported 
the notion that lung-function impairment in juvenile MCTD is common, but mostly mild. We 
believe that the somewhat unexpected finding that 25% of controls had abnormal PFTs 
could be explained by the fact that we did not use mild asthma and smoking as exclusion 
criteria.  
Low values of FVC and TLC were associated significantly with ILD. In contrast, low DLCO was 
not associated with ILD even though it was the most commonly impaired PFT in juvenile 
MCTD. Abnormal DLCO has also been described to occur commonly in other types of 
connective-tissue disease in children. In a cohort of 60 juvenile patients with SLE, Lilleby et 
al. found a low DLCO in 35% and none of them had findings of ILD on HRCT(26). 
Furthermore, in juvenile dermatomyositis, Sanner et al. described low DLCO in half of 59 
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patients without association with ILD(25). Thus, in juvenile MCTD, low DLCO cannot be 
explained by restrictive lung disease alone, but may be due to other causes, such as 
pulmonary vascular disease(28) or structural changes in alveolar membranes(29). In 
addition, in SSc, fibrosis has been shown to be better predicted by FVC than by DLCO(30-33). 
Our data showed no significant progression of ILD over a mean observation period of 8 
years. In adult MCTD, Kawano-Durado et al.(6) found limited ILD progression over 10 years, 
with an increase in lower-lobe ILD score from 7.5 to 11.2%. Reiseter et al.(3) found modest 
progression of ILD in 19% of cases over 6.4 years, with an increase in median extension of 
ILD from 5% to 7%. The presence and extent of ILD are prognostic factors for increased 
mortality in MCTD(2, 3). Our data imply that ILD in juvenile MCTD is mostly stable over long-
term disease duration, but we cannot exclude that mild ILD in these patients should be of 
concern, as lung function declined over time.  
Patients without ILD after mean disease duration of 16 years had more often been treated 
with prednisolone and antimalarial agents than patients with ILD. Although we cannot make 
conclusions based on these associations due to the relatively small sample size and low 
number of patients with ILD, we believe that these are relationships that could be assessed 
in more depth in larger studies. We found no associations between ILD and disease activity 
measurements or smoking status.  Reiseter and colleagues showed male sex, presence of 
anti-Ro52 antibodies, and a high level of anti-RNP antibodies to be predictors for ILD 
progression in adult MCTD(3), but none of these factors were associated with ILD in our 
cohort.   
The present study had two main limitations. The first limitation was the small cohort of 
patients, and especially the results regarding the subgroup of patients with ILD should be 
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interpreted with caution, as these analyses are of more exploratory nature. However, 
compared with other relevant studies, our cohort was the largest cross-sectional study 
carried out on juvenile MCTD. Second, ideally we should have had data on all 52 patients 
also at Time 1, and we cannot exclude that the study was underpowered with regards to 
assessing ILD progression.  
The main strength of our study was that it was the first to compare juvenile MCTD patients 
with a control group. It was also the largest study to assess HRCT and PFT systematically in 
all patients, and the cohort is believed to be representative of juvenile MCTD patients living 
in Norway, as described in more detail previously(17). Progression of pulmonary 
manifestations in juvenile MCTD patients has not previously been reported, and we had a 
long follow-up of 16.2 years from the diagnosis. All HRCTs, from Time 1 and Time 2, were 
examined by the same experienced radiologist using a standardised method.  
In conclusion, this long-term study showed that compared to matched controls, juvenile 
MCTD patients had impaired pulmonary function. ILD was found in 27% of patients, mostly 
as mild disease. The presence and extent of ILD did not progress. These findings suggest that 
ILD is stable in juvenile MCTD, and that the progression and severity of ILD is less prevalent 
than that reported in adult onset MCTD. Our results may imply that asymptomatic juvenile 
MCTD patients with mild ILD can be followed with regular PFTs alone, but repeated HRCT 
should be considered in case of unexplained pulmonary symptoms or reduction in PTFs. 
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Figure 1. HRCT abnormalities in juvenile MCTD.  
 
 
A. ILD extent in percent of total lung parenchyma. B. HRCT image of a typical patient with JMCTD, with a 




Variable JMCTD patients 
n = 52 
Controls  
n = 52 
p value 
 n = 52 n = 52  
Age at onset, years 11.7 (3.1) NA  
Age at diagnosis, years 14.4 (4.4) NA  
Disease duration (from onset) 16.2 (10.3) NA  
Female gender, n (%) 44 (85) 44 (85) 1.00 
BMI, kg/m² 22.7 (3.5) 23.4 (3.0) 0.239 
Height, cm 166.0 (7.5) 170.1 (8.5) 0.016 
Weight, kg 63.0 (12.1) 68.1 (12.1) 0.033 
Current smokers, n (%) 7 (14) 9 (17) 0.586 
Never smokers, n (%) 35 (67) 34 (65) 0.832 
Hemoglobin, g/100ml 13.5 (1.2) 13.6 (1.1) 0.809 
Vigorous physical activity (hours/week) 2.0 (0-25) 2.0 (0-55) 0.400 
Moderate physical activity (hours/week) 2.0 (0-28) 1.2 (0-30.0) 0.278 
Values refer to the mean (SD) or median (min/max range) if not indicated otherwise 









Table 1 Characteristics in patients with juvenile mixed connective tissue disease 








n = 52 
Controls 




FVC, litres 3.4 (0.6) 4.3 (1.0)  <0.001 
FVC% 89 (14.7) 109 (11.9) 20% <0.001 
FEV1, litres  2.9 (0.5) 3.5 (0.8)  <0.001 
FEV1% 89 (13.7) 103 (11.0) 14% <0.001 
FEV1/FVC ratio  0.86 (0.06) 0.82 (0.07)  0.001 
DLCO mmol/kPa 6.8 (1.3) 9.2 (2.4)  <0.001 
DLCO% 73 (12.5) 94 (16.0) 21% <0.001 
DLCO/VA  1.6 (0.2) 1.8 (1.0)  0.282 
DLCO/VA% 88 (12.7) 92 (13.4) 4% 0.207 
TLC, litres   4.8 (1.0) 6.0 (1.2)  <0.001 
TLC%  90 (13.1) 108 (10.6) 18% <0.001 
Abnormal PFT* 36 (69) 13 (25)  <0.001 
FVC <80%, n (%) 11 (21) 0  <0.001 
FEV1 <80%, n (%) 12 (23) 2 (4)  <0.001 
FEV1/FVC <0.70, n (%) 1 (2) 3 (6)  0.617 
DLCO <80%, n (%) 35 (67) 9 (17)  <0.001 
DLCO <70%, n (%) 19 (37) 1 (2)  <0.001 
DLCO/VA <80%, n (%) 12 (23) 8 (15)  0.338 
TLC <80%, n (%) 6 (12) 0  0.009 
6 MWT, meters  634.3 (76.5) 698.9 (86.6)  0.002 







Table 2 Pulmonary function after mean 16.2 years of disease duration in juvenile 
MCTD patients and controls 
Values refer to the mean (SD) if not indicated otherwise 
*FVC, FEV1 and/or DLCO <80% of expected value, and/or FVC/FEV1 < 70% of predicted  
MCTD, mixed connective tissue disease; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 
second; VC, vital capacity; DLCO, diffusion capacity of carbon monoxide; VA, alveolar volume; TLC, total 







  n (%) 
ILD on HRCT* 14 (27) 
Ground glass attenuation 2 (4) 
Reticular pattern present 13 (25) 
Reticular pattern grade 1 12 (23) 
Reticular pattern grade 2 6 (12) 
Reticular pattern grade 3 1 (2) 
Interlobular septal thickening 0 
Airspace consolidations  0 
Bronchiectasis 1 (2) 
*Defined as reticular pattern and/or ground glass attenuation, 
interlobular septal thickening, airspace consolidations and 
bronchiectasis 
HRCT, high resolution computed tomography; ILD, interstitial 
lung disease 
  
Table 3 HRCT findings in 52 juvenile MCTD 









p value  
Characteristics at examination    
Female gender, n (%) 34 (90) 10 (71) NS 
Age, years 27.1 (10.3) 30.4 (10.2) NS 
Disease duration (from symptom onset) 15.1 (10.2) 19.4 (10.2) NS 
BMI, kg/m² 23.3 (3.0) 23.7 (2.9) NS 
Current smokers, n (%) 3 (8) 4 (29) NS 
Never smokers, n (%) 26 (68) 9 (64) NS 
SLE-like disease, n (%) 22 (58) 5 (36) NS 
SSc-like disease, n (%) 22 (58) 14 (100) 0.025 
PM-like disease, n (%) 2 (5) 0 NS 
Pulmonary function    
Impaired PFT^, n (%) 27 (73) 9 (64) NS 
DLCO < 80%, n (%) 26 (70) 9 (64) NS 
DLCO <70%, n (%) 13 (34) 6 (43) NS 
FVC < 80%, n (%) 5 (14) 6 (43) 0.023 
TLC <80%, n (%) 1 (3) 5 (36) 0.002 
FEV1/FVC < 0.70 n (%) 1 (3) 0 NS 
6MWT, meters 626.5 (77.1) 626.9 (79.8) NS 
Disease activity at examination     
Active disease, n (%) 26 (68) 9 (64) NS 
Number of active joints 0 (0-11) 0 (0-2) NS 
Anti-RNP, titre x10
3
 U/L 83.5 (0-240) 234.0 (17-240) NS 
ESR, mm/hour 9.0 (2-54) 8.0 (2-30) NS 
CRP, mg/l 0.7 (0-15) 0.7 (0-9.3) NS 
Anti-Ro52 positive, n (%) 1 (3) 0 NS 
PGA, 10 cm VAS 1.5 (0-58.0) 2.9 (0.2-5.7) NS 
Rodnan skin score 0 (0-4) 0 (0-11) NS 
Values refer to the mean (SD) or median (min/max range) if not indicated otherwise 
^FVC, FEV1  and/or DLCO <80% of predicted, and/or FEV1/FVC  <0.7 
Anti-RNP, anti-ribonucleoprotein; BMI, body mass index; PFT, pulmonary function test; FVC, forced vital capacity; FEV1, 
forced expiratory volume in 1 sec; DLCO, diffusion capacity of carbon monoxide; VA, alveolar volume; TLC, total lung 
capacity; 6MWT, 6 min walk test; ESR, erythrocyte sedimentation rate; CRP, c-reactive protein; PGA, physician global 
assessment of disease activity; VAS, visual analogue scale 
 
  
Table 4 Patient and disease characteristics in 52 patients with juvenile MCTD with and 





 Time 1 Time 2  p value  
Disease duration at time of HRCT  8.8 (0.6-33.6) 17.8 (3.1-40.2) NA 
Disease duration at time of PFT 11.6 (3.3-30.9) 17.7 (2.3-41.2) NA 
Age at PFT examination 21.9 (6.5) 32.2 (6.7) NA 
Age at HRCT  21.7 (7.3) 29.3 (8.6) NA 
Time between HRCT scans  8.3 (2.7) NA 
Time between PFT  10.3 (1.0) NA 
FVC % 92.7 (11.4) 85.6 (15.6) 0.004 
FEV1 % 94.6 (12.0) 85.9 (10.3) 0.001 
FEV1/FVC ratio 0.87 (0.05) 0.84 (0.05) NS 
DLCO % 72.2 (14.0) 70.5 (11.3) NS 
DLCO/VA % 88.2 (15.7) 88.2 (15.1) NS 
ILD present, n (%) 9 (24) 10 (27) NS 
Ground glass attenuation, n (%) 3 (8) 0 NS 
Reticular pattern, n (%) 7 (19) 10 (27) NS 
Reticular pattern grade 1, n (%) 8 (22) 9 (24) NS 
Reticular pattern grade 2, n (%) 4 (11) 6 (16) NS 
Reticular pattern grade 3, n (%) 0 1 (3) NS 
Percentage of lung parenchyma with ILD 2.0 (1-18) 4.0 (1-18) NS 
Numbers are in mean (SD) or median (min/max range) unless stated otherwise 
HRCT, high resolution computed tomography; PFT, pulmonary function tests; ILD, interstitial 
lung disease; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; DLCO, 
diffusion capacity of carbon monoxide; VA, alveolar volume 
 
Table 5. Progression of HRCT findings (n = 37) and changes in pulmonary 
function tests (n = 38) in patients with juvenile MCTD 
 
